Company intelligence / Profile preview
Intech Biopharm Corporation
Taipei, Taipei City, Taiwanmarketscreener.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Intech Biopharm has developed and commercialized products including Duasma and Synvent. Their product SYN006 has entered Phase III clinical trials. The company has invested over $80 million to build a state-of-the-art factory following US FDA and EU GMP standards[6].
- Therapeutic areas
- Pulmonology
- Modalities
- Metered-dose inhalers (MDI)Dry powder inhalers (DPI)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Intech Biopharm Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intech Biopharm Corporation.